Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type

Eva Gupta, Joseph Accurso, Jason Sluzevich, David M. Menke, Han W. Tun

Research output: Contribution to journalArticle

14 Scopus citations

Abstract

Primary cutaneous diffuse large B-cell lymphoma, leg type (PCDLBCL-LT) is a rare diffuse large B-cell lymphoma confined to the skin of the legs. The typical presentation is characterized by solitary or multiple growing plaques, usually confined to one leg. We report a case of PCDLBCL-LT of activated B-cell subtype characterized by multiple local relapses in the legs, initially, and systemic relapses about seven years after the diagnosis. Local relapses were sensitive to radiation therapy. Cutaneous and systemic relapses responded well to immunomodulatory therapy with lenalidomide followed by Bruton’s tyrosine kinase inhibition with ibrutinib. Ibrutinib is the only treatment that resulted in long-lasting complete remission. Lenalidomide and especially ibrutinib appear to have a significant activity against this lymphoma and should be incorporated in the treatment of this resistant and aggressive lymphoma. To our knowledge, this is the first case of PCDLBCL-LT reported in the literature exhibiting a complete response to ibrutinib.

Original languageEnglish (US)
Article number6067
Pages (from-to)164-166
Number of pages3
JournalRare Tumors
Volume7
Issue number4
DOIs
StatePublished - Dec 29 2015

Keywords

  • Cutaneous diffuse large B-cell lymphoma
  • Ibrutinib
  • Lenalidomide

ASJC Scopus subject areas

  • Histology
  • Oncology

Fingerprint Dive into the research topics of 'Excellent outcome of immunomodulation or Bruton’s tyrosine kinase inhibition in highly refractory primary cutaneous diffuse large B-cell lymphoma, leg type'. Together they form a unique fingerprint.

  • Cite this